首页> 美国政府科技报告 >Target Identification for Differentiation Therapy of Prostate Cancer
【24h】

Target Identification for Differentiation Therapy of Prostate Cancer

机译:前列腺癌分化治疗的靶点鉴定

获取原文

摘要

Work carried out under this grant showed that hyperphosphorylated Rb interacts with pp32 but not with the closely related proteins pp32r1 and pp32r2. Furthermore, pp32-Rb interaction inhibits the apoptotic activity of pp32 and stimulates proliferation. These results suggest a mechanism whereby cancer cells gain both a proliferative and survival advantage when Rb is inactivated by hyperphosphorylation. Further extension of these studies showed that pp32 increases androgen receptormediated transcription and the retinoblastoma protein modulates this activity. Furthermore, the results suggest that pp32 and the retinoblastoma protein may be part of a multiprotein complex that coordinately regulates nuclear receptor-mediated transcription and mRNA processing. Together, these findings indicate that the pp32-Rb interaction could serve as a drug target in prostate cancer.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号